Stone Ridge Asset Management LLC purchased a new position in shares of Iradimed Corp (NASDAQ:IRMD) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 26,141 shares of the medical equipment provider’s stock, valued at approximately $396,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Ameriprise Financial Inc. lifted its position in Iradimed by 32.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 456,810 shares of the medical equipment provider’s stock worth $4,386,000 after buying an additional 113,190 shares in the last quarter. Unison Advisors LLC acquired a new position in Iradimed during the 4th quarter worth about $443,000. EAM Investors LLC acquired a new position in Iradimed during the 4th quarter worth about $457,000. Eversept Partners LLC acquired a new position in Iradimed during the 4th quarter worth about $774,000. Finally, Ranger Investment Management L.P. acquired a new position in Iradimed during the 4th quarter worth about $238,000. Institutional investors and hedge funds own 16.34% of the company’s stock.
Iradimed stock opened at $14.40 on Friday. Iradimed Corp has a 1 year low of $7.85 and a 1 year high of $15.85. The stock has a market cap of $152.71, a price-to-earnings ratio of 160.00 and a beta of 1.55.
In other Iradimed news, insider Louis S. Waldman sold 30,000 shares of the company’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $13.83, for a total transaction of $414,900.00. Following the transaction, the insider now directly owns 5,221 shares in the company, valued at approximately $72,206.43. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 60.10% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Friday, January 26th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $17.33.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iradimed Corp (NASDAQ:IRMD).
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.